autologous dendritic cells expressing TAT mRNA

Autologous dendritic cells expressing TAT mRNA is an investigational therapeutic HIV-1 vaccine consisting of autologous monocyte-derived dendritic cells electroporated with mRNA encoding the early HIV-1 regulatory and accessory proteins Tat, Rev, and Nef. Developed through a collaboration between Erasmus MC and Vrije Universiteit Brussel, the vaccine is designed to present these viral antigens to the patient's immune system to elicit or enhance antigen-specific CD4+ and CD8+ T-cell responses. By targeting proteins expressed early in the viral life cycle, the vaccine aims to improve immune control of HIV-1 replication, particularly in patients undergoing analytical treatment interruption (ATI) from combination antiretroviral therapy (cART). Clinical studies, such as the Phase I/IIa DCTRN trial, have demonstrated the safety and immunogenicity of this approach.

Other names

DC vaccine with TAT, REV, and NEF mRNAautologous dendritic cells electroporated with HIV early gene (Tat, Rev, Nef) mRNATat/Rev/Nef-DC